E-LIB Suche - Ergebnisse für: Humphrey, Rachel W.

1

Maximizing the value of phase III trials in immuno-oncology..:

Atkins, Michael B ; Abu-Sbeih, Hamzah ; Ascierto, Paolo A...
Journal for ImmunoTherapy of Cancer. 10 (2022) 9 - p. e005413 , 2022

Link: https://doi.org/10.1136/..

2

Defining tumor resistance to PD-1 pathway blockade: recomme..:

Kluger, Harriet M. ; Tawbi, Hussein A. ; Ascierto, Maria L....
Journal for ImmunoTherapy of Cancer. 8 (2020) 1 - p. e000398 , 2020

Link: https://doi.org/10.1136/..

3

Recommended changes to oncology clinical trial design: Revo..:

Ratain, Mark J. ; Humphrey, Rachel W. ; Gordon, Gary B....
European Journal of Cancer. 44 (2008) 1 - p. 8-11 , 2008

Link: https://doi.org/10.1016/..

4

A phase I trial of the pharmacokinetics, toxicity, and acti..:

Humphrey, Rachel W. ; Wyvill, Kathleen M. ; Nguyen, Bach-Yen...
Antiviral Research. 41 (1999) 1 - p. 21-33 , 1999

Link: https://doi.org/10.1016/..

5

Relative Potency of Protease Inhibitors in Monocytes/Macrop..:

Perno, Carlo-Federico ; Newcomb, Fonda M. ; Davis, David A....
The Journal of Infectious Diseases. 178 (1998) 2 - p. 413-422 , 1998

Link: https://www.jstor.org/st..

6

Detection of Serum Antibodies to a Kaposi's Sarcoma‐Associa..:

Davis, David A. ; Humphrey, Rachel W. ; Newcomb, Fonda M....
The Journal of Infectious Diseases. 175 (1997) 5 - p. 1071-1079 , 1997

Link: https://doi.org/10.1086/..

7

ANALYSIS OF HUMAN HERPESVIRUS-8 INFECTION IN CHILDREN AND A..:

Humphrey, Rachel W. ; Davis, David A. ; Newcomb, Fonda M....
Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 14 (1997) 4 - p. A34 , 1997

Link: https://doi.org/10.1097/..

8

Detection of Serum Antibodies to a Kaposi's Sarcoma-Associa..:

Davis, David A. ; Humphrey, Rachel W. ; Newcomb, Fonda M....
The Journal of Infectious Diseases. 175 (1997) 5 - p. 1071-1079 , 1997

Link: https://www.jstor.org/st..

9

Maximizing the value of phase III trials in immuno-oncology..:

Atkins, Michael B ; Abu-Sbeih, Hamzah ; Ascierto, Paolo A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528604/. , 2022

Link: http://www.ncbi.nlm.nih...

10

Defining tumor resistance to PD-1 pathway blockade: recomme..:

Kluger, Harriet M ; Tawbi, Hussein A ; Ascierto, Maria L...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174063/. , 2020

Link: http://www.ncbi.nlm.nih...

11

Probody(™) Therapeutics: An Emerging Class of Therapies Des..:

Autio, Karen A ; Boni, Valentina ; Humphrey, Rachel W.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436251/. , 2019

Link: http://www.ncbi.nlm.nih...

12

Recommended changes to oncology clinical trial design: Revo..:

Ratain, Mark J ; Humphrey, Rachel W ; Gordon, Gary B...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673461. , 2007

Link: http://www.ncbi.nlm.nih...

13

COLLABORATIVE EFFORTS BETWEEN THE UNITED STATES AND UNITED ..:

Kain, John S. ; Willington, Steve ; Clark, Adam J....
Bulletin of the American Meteorological Society. 98 (2017) 5 - p. 937-948 , 2017

Link: https://www.jstor.org/st..

14

O-107 Adjuvant targeted therapy in unresectable lung cancer..:

Rigas, James R. ; Denham, Claude A. ; Rinaldi, David...
Lung Cancer. 41 (2003) - p. S34 , 2003

Link: https://doi.org/10.1016/..

15

Maximizing the value of phase III trials in immuno-oncology..:

James L Gulley ; James Larkin ; Leisha A Emens...
https://jitc.bmj.com/content/10/9/e005413.full. , 2022

Link: https://doi.org/10.1136/..